Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$57.02 USD

57.02
591,898

+0.73 (1.30%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $57.03 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

3 Reasons to Hold Abiomed (ABMD) Stock in Your Portfolio

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Anirudha Bhagat headshot

Solid Net Profit Margin Makes These 4 Stocks Worth Buying Now

Let's take a look at four Buy-ranked stocks - Industrias Bachoco, S.A.B. de C.V. (IBA), AMN Healthcare Services, Inc. (AMN), Veritiv Corporation (VRTV) and CONSOL Energy Inc. (CEIX) - with solid net profit margins.

Here's Why You Should Hold on to Chemed (CHE) Stock Now

Investors are optimistic about Chemed's (CHE) better-than-expected earnings and impressive Roto-Rooter results.

Medtronic (MDT) Obtains U.S. Distribution Rights for BioButton

Medtronic's (MDT) new deal with BioIntelliSense will ensure accessibility to BioButton for continuous vital sign measurements of general care patients in the United States.

Boston Scientific (BSX) Grows Operationally Amid Macro Issues

In the Asia Pacific region, Boston Scientific (BSX) grows operationally with notable performance in Japan, India and the ASEAN countries.

Patterson Companies (PDCO) Q1 Earnings & Sales Miss Estimates

Patterson Companies' (PDCO) fiscal first-quarter 2023 results were adversely impacted by unfavorable currency movements.

Cooper Companies (COO) Q3 Earnings & Revenues Top Estimates

Despite a decline in the bottom line, Cooper Companies' (COO) fiscal third-quarter earnings reflect solid segmental performance.

Veeva Systems (VEEV) Beats on Q2 Earnings, Revises FY23 View

Veeva Systems' (VEEV) fiscal Q2 results reflect impressive performances by both of its segments.

Henry Schein (HSIC) Inks Deal to Acquire Midway Dental Supply

Henry Schein's (HSIC) acquisition of Midway Dental Supply complements its efforts to offer products and services that deliver more effective, high-quality patient care.

Here's Why You Should Retain AngioDynamics (ANGO) Stock Now

AngioDynamics (ANGO) continues to benefit from strength in segments but forex remains a woe.

Cigna (CI) to Widen Access to Individual Health Plans in 2023

Cigna (CI) unveils enhanced individual and family health plans for its customers to opt for in the 2023 Open Enrollment Period. CI will enter newer counties and states to offer better health outcomes.

Bruker (BRKR) Debuts Innovations for Proteomics & Metabolomics

Bruker's (BRKR) novel nanoElute 2 and next-generation MetaboScape 2023 release are likely to offer enhanced workflows for proteomics and metabolomics applications.

Reasons Why You Should Retain ResMed (RMD) Stock For Now

Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.

Haemonetics (HAE) Inks Epic Deal to Expand Hospital Business

According to Haemonetics (HAE), amid the complex situation of blood supply and staffing shortages, the SafeTrace Tx transfusion management system is set to provide more transfusion safety and efficiency.

Catalent (CTLT) Stock Down Despite Q4 Beat: Will it Recover?

Catalent's (CTLT) fiscal fourth-quarter earnings beat but the stock falls 7.4% following the earnings release on Aug 29. Here we discuss the factors that are set to guide its share price going forward.

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

Encompass Health's (EHC) Future Hospital to Serve Pennsylvania

Encompass Health (EHC) decides to develop a 50-bed inpatient rehabilitation hospital in Pennsylvania to better serve the rehabilitative needs of the local communities.

Myriad Genetics (MYGN) Gets Extensive Coverage for BRACAnalysis

Myriad Genetics' (MYGN) BRACAnalysis gained expanded coverage from MHLW to identify breast cancer patients who are eligible for treatment with Lynparza in Japan.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.

What's in Store for Patterson Companies (PDCO) in Q1 Earnings?

Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at the Animal Health segment.

Catalent (CTLT) Q4 Earnings Beat Estimates, Revenues Lag

Catalent's (CTLT) robust performance across most of its segments drives its fourth-quarter fiscal 2022 top line.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Humana (HUM) Brand to Open Senior-Centric Centers in Arizona

Humana's (HUM) CenterWell brand announces plans to open nine centers by early 2023 to serve the aging population of the Phoenix region.

Here's Why Investors Should Retain Myriad Genetics (MYGN) Now

Investors are optimistic about Myriad Genetics' (MYGN) better-than-expected results and strong testing volumes.

Veeva Systems (VEEV) to Report Q2 Earnings: What's in Store?

Veeva Systems' (VEEV) Q2 earnings are likely to have been driven by strength in its commercial business.